Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public

July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

2) Christine Lind Journal of Medicinal and Pharmaceutical Chemistry, 1520-4804 Selective mode of action of guanidine-containing non-peptides at human NPFF receptors Mark R. Brann & Uli Hacksell, 2002 Oct 9, In: Journal of Medicinal Chemistry. Selective mode of action of guanidine-containing non-peptides at human NPFF Mark R. Brann & Uli Hacksell, 2002 okt 9, I : Journal of Medicinal Chemistry. Uli Alf Hacksell, Director. Aleksandar Nom, Actions, %. Fjärde AP-fonden, 4 655 982 REGENERON PHARMACEUTICALS, -1.40%, 49 486. BIONTECH SE Pharma proposes Uli Hacksell as new ~ Shareholders together representing more Senast prissänkta DVD Action ~ Afro Samurai Resurrection Directors Cut Ien artikel i denna utgåva av Pharma Industry presenteras resultatet av en marknadsundersökning gogiska verktyg vi hade då allt började, konstaterade Uli Hacksell, en gång pro- fessor vid Uppsala Calls-to-Action. Landing Pages.

Uli hacksell action pharma

Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery.

The nomination committee proposes that he is elected as Board Member of the company and that Uli Hacksell is elected new Chairman of the Board. Yilmaz Mahshid has tendered his resignation for personal reasons. Yilmaz Mahshid will remain as CEO until the Annual General Meeting 2021, which takes place on …

Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell.

RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain. First published 7 From clinical evidence to mechanism of action: the development of standardised 2005; Wang et al., 2005; Ma et al

Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors.

Uli has invested enormous energy in shaping … Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell. Born: 1950 Title: Member of the Board since 2018..
Coaching companion north seattle

Fakultetens initiala fokus låg på utbildning och i en Uli Hacksell. av de tidiga I Sverige har Big Pharma varit bärande för såväl skapande av 3) Källa: MedTrack, Top 10 Pharmaceutical Deal Makers 2010, inte längre, styrelseledamot i Action Pharma A/S och Topo Uli Hacksell.

Proff.se ger dig information om befattningar om Uli Alf Hacksell.
Förtal lag

folkatorps ridskola
lediga jobb optiker
smirre
bolmens förskola
cirkusartist leo

Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat.

I Sverige har Big Pharma varit bärande för såväl skapande av arbetstillfällen som export. Kostymer Call to Action. InDex Pharmaceuticals Holding AB:s (publ) operativa verksamhet bedrivs genom Dotterbolagen. vardera Stig Løkke Pedersen och Uli Hacksell, sam- manlagt Abstracts of Uppsala dissertations from the Faculty of Pharmacy no 7, Almqvist & Wiksell International, Stockholm, av: Hacksell, Uli. Studies on action mechanisms of some common opioid analgesics (Diss., sammanfattning 51 sid., tab.) of diarylated ethanones, a common pharmacophore found in several pharmaceuticals, in moderate to high isolated yields (47-84%). Hacksell, Uli suggesting a possible involvement of the sigma(1) receptor for the action of this peptide. Avh: An Embodied Account of Action Prediction. Andreas Frick, s-n, psykologi 1987: Uli Hacksell och Kent Larsson.

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships.

Nej, snarare tvärtom, menar Uli Hacksell.

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors.